biostudies-literatureSpicer JDHealth Research BoardNCI NIH HHS1240-1252https://www.ebi.ac.uk/biostudies/studies/S-EPMC11512588biostudies-literatureUnknown404(10459)<h4>Background</h4>At the first interim analysis of the KEYNOTE-671 trial, adding perioperative pembrolizumab to neoadjuvant chemotherapy significantly improved event-free survival in participants with early-stage non-small-cell lung cancer (NSCLC). We report overall survival and health-related quality of life outcomes from the second interim analysis.<h4>Methods</h4>KEYNOTE-671 was a global phase 3 trial done at 189 medical centres. Eligible participants (aged ≥18 years) with resectable stage II, IIIA, or IIIB (N2) NSCLC were randomly assigned (1:1) to four cycles of neoadjuvant pembrolizumab (200 mg administered intravenously every 3 weeks) plus cisplatin-based chemotherapy followed by surgery and 13 cycles of adjuvant pembrolizumab (200 mg administered intravenously every 3 weeks) or toLancet (London, England)Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.PMC11512588P30 CA008748CTIC-2021-002Teixeira CWesseler CCicenas SGrohe CRathnasabapathy CAlves GAlekshun TZurawski BSiegel RPastor ASakao YLevenko OChaft JEVogel GDeschepper KJain SHui RDuchemann BDelmonte AHorio YKuroda HRodriguez-Abreu DJain KSerke MFurqan MHu JBylicki OMartinengo GGilli MHuang HCSaji HMakles KMartinez Marti ASpicer JDGal CGuisier FKaywin PZhu YPuig JFaria LIordan IHegmane ABerceanu-Ion RSibille AZhao QZhao GShio YBonnet RBai JBerard HWong MRittmeyer AKristedja TCobb PGregorc VChaves FChiang CLLee SHKolesnik OVanakesa TSantoro Ade Paiva Junior TKoontz MThiberville LAfanasyev SLima IO'Day SVillaruz LGreystoke AKeresztes RGuimaraes JLLambrechts MTsuboi MCalles Blanco ANishio WSangal AArora ASardenberg RBosch Barrera JRao SFrohling KPMolina JMennecier BVarela MCiuleanu THammoud ZTCuevo RUrsol GIntagliata SRadhi STanaka FChen QSavvides PParamonov VChen KChen JCortinovis DLaktionov KChen HFernando HPollock TChaft JLi SIkeda NFlores MBondarenko IDuvivier HOgliari FHan JYRybkin IGalamaga RCronemberger EHMa SReck MLuft AHeng FYJiang TMigliorino MRLou YYSuzuki HHorinouchi HCarvalho LScheusan RGentzler RRoca EBrocca CCoetzee CPang YKVansteenkiste JSmagina MLiao BCWehler TEigendorff EFinley GFix PDemedts IKrasnohrud YCuffe SMorbeck ILevchenko ECollins DRitgen MBulotta AAnderson ILiu GAhmed SGarassino MCErnani VSignorelli DWirtz HMartinengo GLLehmann MNovello SZhang LGoranov BTabacof JO'Brien MFourie SCiubotaru ETauscher DCebotaru CCarcereny EMisleh JReinacher-Schick AWermke MKaraseva NMueller AStencel KArunachalam AUngureanu AJacobs CLowczak AFedenko AMajem Tarruella MFranke FFaehling MTrukhin DKim JVillalona-Calero MSchiller JWeksler BPope TSokur IRuff PSugio KKeller SMTatangelo MShim BYKollmeier JVoitko NTsai CLCharu VHalmos BKazmi SGanti AKStampleman LStarodub AWang CCAraujo LHBelonogov ADooms CArkhipov AKryzhanivska ALangleben AKomiya TDutra CSchumacher LWang QWang SWang WGuarino MGrisanti STan LMatias DYang JFerrari VFerrara RChen KNPawlak IYang YTakamochi KWakelee HCiurescu IMazieres JMuto SGao SSurmont VMajem MSamkari AChiu CHShimizu JBernabe Caro RZemaitis MRich PNiu JCostas KGarassino MPiantedosi FSrkalovic GYu KLCostin DSpicer JGirard NOkada MLiberman MBegin PGanea DNesterova ALiu-Dumlao TKato TDe Marchi PRMYan XBryl MKEYNOTE-671 InvestigatorsMazilu LLo Russo GZasadny XLang SNadal Alforja EDias JGianni LKhan SfalseNeoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.<h4>Background</h4>At the first interim analysis of the KEYNOTE-671 trial, adding perioperative pembrolizumab to neoadjuvant chemotherapy significantly improved event-free survival in participants with early-stage non-small-cell lung cancer (NSCLC). We report overall survival and health-related quality of life outcomes from the second interim analysis.<h4>Methods</h4>KEYNOTE-671 was a global phase 3 trial done at 189 medical centres. Eligible participants (aged ≥18 years) with resectable stage II, IIIA, or IIIB (N2) NSCLC were randomly assigned (1:1) to four cycles of neoadjuvant pembrolizumab (200 mg administered intravenously every 3 weeks) plus cisplatin-based chemotherapy followed by surgery and 13 cycles of adjuvant pembrolizumab (200 mg administered intravenously every 3 weeks) or to2024-01-01T00:00:00Z2024 Sep2026-06-03T23:24:00.785Z2026-05-03T03:10:48.182ZS-EPMC115125883928878110.1016/s0140-6736(24)01756-210.1016/S0140-6736(24)01756-2